Marrero Jorge A, Pelletier Shawn
Division of Gastroenterology, Department of Internal Medicine, 3912 Taubman Center, University of Michigan, Ann Arbor, MI 48109, USA.
Clin Liver Dis. 2006 May;10(2):339-51, ix. doi: 10.1016/j.cld.2006.05.012.
The number of patients who have hepatocellular carcinoma (HCC) is expected to more than double over the next 1 to 2 decades. Patients who have cirrhosis, regardless of cause, are at the highest risk for developing HCC. This article discusses surveillance of these patients for HCC by alpha-fetoprotein and ultrasound, evaluation using imaging, classification of HCC using the Barcelona staging classification, and treatment. Resection, transplantation, and percutaneous ablation are considered curative interventions and are applied to about 30% of all patients who have HCC. Currently, there is no standard therapy for advanced HCC.
预计在未来1至2十年间，肝细胞癌（HCC）患者数量将增加一倍多。无论病因如何，患有肝硬化的患者发生HCC的风险最高。本文讨论了通过甲胎蛋白和超声对这些患者进行HCC监测、使用影像学进行评估、使用巴塞罗那分期分类对HCC进行分类以及治疗。切除、移植和经皮消融被视为根治性干预措施，适用于所有HCC患者的约30%。目前，晚期HCC尚无标准治疗方法。
